Medicine & Health

Background: Type I interferon (IFN-I) pathway activation is a hallmark of systemic lupus erythematosus (SLE), yet the widely used interferon gene signature (IGS) score is binary and fails to distinguish imminent severe flares from mild activity fluctuations. Siglec-1 (CD169/sialoadhesin), a monocyte surface receptor upregulated by IFN-α/β, has emerged as a quantitative, dynamic marker of IFN-I pathway activation. Its soluble form (sCD169) is measurable in serum and reflects cumulative IFN-I exposure more accurately than single-timepoint IGS.

Hypothesis: Serial serum sCD169 measurements combined with ex vivo plasmacytoid dendritic cell (pDC) IFN-α secretion capacity (stimulated via TLR7/9 agonists) will predict lupus flare severity — distinguishing mild (ΔSLEDAI 4–6) from severe (ΔSLEDAI ≥8 or major organ involvement) — 4–10 weeks before clinical deterioration, with AUROC >0.85 for severe flare discrimination.

Rationale: (1) sCD169 trajectory slope reflects the rate of IFN-I pathway escalation, not merely its current state; (2) pDC functional reserve — measured as maximal stimulated IFN-α output — captures the amplification potential that determines whether subclinical IFN activation will cascade into severe multisystem flare; (3) the ratio of sCD169 trajectory slope to pDC functional capacity creates a dimensionless "IFN amplification index" that integrates both ongoing activation and amplification headroom.

Testable predictions: (P1) sCD169 slope >2 SD above patient baseline over 4 consecutive weeks will precede SLEDAI increase by 4–10 weeks with sensiti

IF a minimal recombinant protein cocktail comprising GDF11 (0.1 mg/kg), TIMP2 (1 µg/kg), and MANF (1 mg/kg) is administered intravenously (3×/week, 4-week induction followed by 2×/week maintenance for 8 weeks) to aged (22–24 month) male C57BL/6J mice,

THEN multi-tissue epigenetic clock age — measured by Horvath DNAm clock across liver, heart, and hippocampus — will be reduced by ≥15% relative to vehicle-treated aged controls, with concurrent: (a) restoration of H3K27me3 enrichment at PRC2-regulated developmental gene loci in liver and cardiac tissue, (b) increased chromatin accessibility (ATAC-seq) at muscle and neural stem cell identity gene loci, (c) ≥20% restoration of aged satellite cell and hippocampal neural progenitor cell (NPC) proliferative capacity, and (d) reduction in global DNA methylation entropy (epigenetic noise) at CpG sites that diverge during aging,

BECAUSE of the following mechanistic chain:

1. Systemic GDF11 levels decline with age and their restoration via recombinant delivery activates SMAD2/3 nuclear translocation, which recruits Polycomb Repressive Complex 2 (PRC2/EZH2) to re-establish H3K27me3 at developmental gene promoters that become aberrantly demethylated (chromatin-opened) with aging — directly repairing the epigenetic drift that heterochronic parabiosis reverses (GDF11 reverses age-related cardiac hypertrophy and muscle dysfunction)[https://doi.org/10.1016/j.cell.2013.04.015](GDF11 restores satellite cell function in aged muscle)[https://doi.org/10.1126/science.1251152]

2. TIMP2, a circulating factor enriched in young blood, inhibits MMP

IF a protein language model (PLM)-guided, activity-enhanced GLO1 variant — engineered using PLM-identified substitutions that improve catalytic efficiency without altering cofactor selectivity (zinc/GSH), and delivered as lipid nanoparticle (LNP)-encapsulated modified mRNA, targeting liver and vascular endothelium — is administered to 18-month-old male and female C57BL/6J mice via repeated intravenous injection (weekly for 8 weeks),

THEN a measurable reduction (≥30%) in tissue methylglyoxal (MG) levels, MG-derived hydroimidazolone-1 (MG-H1) adducts, and Nε-carboxyethyl-lysine (CEL) AGEs will be detected in aortic and hepatic tissue, accompanied by improved vascular compliance (pulse wave velocity) and reduced plasma dicarbonyl stress markers,

BECAUSE the following causal chain operates:

1. PLMs can systematically identify amino acid substitutions that enhance enzyme catalytic activity — demonstrated for Uracil-N-glycosylase (UNG), where PLM-guided substitutions dramatically reduced the experimental screening burden while yielding verified activity-enhancing variants (PLM-assisted enzyme engineering reduces burden of identifying activity-enhancing substitutions)[https://doi.org/10.1101/2023.10.29.564583]; the same computational framework is substrate-agnostic and applicable to any enzyme whose sequence is embedded in PLM training corpora, including GLO1 (UniProt P78375).

2. Aging tissues accumulate methylglyoxal as a consequence of declining GLO1 activity — this accumulated reactive dicarbonyl pool constitutes a form of chemical damage distinct from stable AGE cr

IF a novel brain-penetrant, non-nucleotide cGAS inhibitor bearing an N-(4-(spiro[3.3]heptan-2-yl)pyridin-2-yl)acetamide scaffold — computationally optimized for CNS exposure (CNS MPO score ≥4.0, predicted P-gp non-substrate, tPSA <60 Ų, logP 2.0–4.0, MW <400 Da for evolved lead), administered via oral gavage at a dose range informed by in vitro IC₅₀ values against recombinant human cGAS (residues 150–522) — is administered to aged (22–24 month) male and female C57BL/6J mice carrying accumulated chronic neuroinflammatory damage,

THEN a measurable reversal of established CNS cGAS-STING pathway hyperactivation will be observed — specifically: ≥40% reduction in brain-resident IFN-β, CXCL10, and IL-6 protein levels by multiplex ELISA; ≥30% reduction in IBA-1⁺ microglial density and shift from amoeboid to ramified morphology by immunohistochemistry; and ≥20% improvement in spatial memory index in Morris Water Maze versus aged vehicle controls — within 8 weeks of continuous treatment,

BECAUSE the following causal chain is supported:

1. Aged post-mitotic neurons, astrocytes, and microglia accumulate cytosolic DNA species — including nuclear envelope rupture-derived chromatin fragments, ruptured micronuclei, and mitochondrial DNA (mtDNA) escapees — that constitutively activate the cGAS catalytic domain (residues 150–522, ATP/GTP binding site) in a manner that is independent of new DNA damage; this accumulation is a consequence of already-accrued damage that persists even after upstream insults are controlled (finding from literature task output describing cGAS as the cytos

IF a self-inactivating AAV6-packaged adenine base editor (ABE8e) cassette — engineered with a dual-logic circuit comprising (i) an HSC-restricted synthetic promoter (RUNX1-SCL composite element) driving ABE8e expression, (ii) a single guide RNA (sgRNA) targeting the DNMT3A R882H or TET2 loss-of-function hotspot codon, and (iii) a secondary embedded "self-destruct" protospacer within the ABE8e coding sequence itself that is corrected from a functional to a non-functional reading frame upon base editor activity — is delivered via direct intra-femoral or intravenous injection into aged (18–22 month) C57BL/6J mice with confirmed CHIP clones,

THEN targeted A•T-to-G•C correction of DNMT3A R882H (or analogous TET2 frameshift rescue) will be detected in ≥10% of bone marrow HSCs (Lin⁻Sca1⁺cKit⁺; LSK fraction) within 8 weeks post-injection, with subsequent clonal contraction of the corrected mutant clone measurable by variant allele frequency (VAF) tracking via deep amplicon sequencing, and simultaneous transcriptional silencing of the ABE8e transgene within 4–6 weeks of initial expression, eliminating persistent on-target and off-target editing risk,

BECAUSE the causal chain proceeds as follows:

1. AAV6 preferentially transduces murine HSCs in the bone marrow niche following systemic or intra-osseous delivery, as demonstrated by AAV6's established use with Cas9 RNP and HDR templates achieving efficient on-target integration in CD34⁺/HSC-like cells under the control of lineage-restricted promoters such as CD68S (Engineering monocyte/macrophage-specific GBA expression in HSCs)[

IF a computationally designed quadruple-domain chimeric outer membrane protein — TOMM20(1–33)-[G4S]4-TAT(YGRKKRRQRRR)-[G4S]4-C2(299–387)-[G4S]4-LIR-decoy(DDFELL) (hereafter "TC2L"), where the LIR-decoy is a hexapeptide competitive inhibitor of LC3-family autophagy receptors — is expressed on the outer mitochondrial membrane of C2C12 myoblast-derived donor mitochondria via lentiviral transduction (EF1α promoter, N-terminal HA tag) and delivered as three intramyocardial injections (1×10⁹ organelles per dose; days 0, 7, 14) to 22-month-old male C57BL/6J mice with isoproterenol-induced cardiac injury (80 mg/kg s.c. ×2 days; target: 20–30% LVEF reduction),

THEN, compared to wild-type C2C12 mitochondria and vehicle controls:

1. Donor mtDNA retention (assessed by SNP-specific qPCR at mt-CO1 locus) will be ≥3-fold higher at 4 weeks post-final injection (vs. wild-type mitochondria which are predicted to show near-complete clearance by week 2),
2. Cardiac Complex I and Complex IV activity (Seahorse XF96 at 4 weeks) will be restored to ≥70% of young (4-month) reference levels (vs. ≤45% in wild-type mitotherapy and ≤30% in vehicle),
3. Left ventricular ejection fraction (echocardiography, 4-week endpoint) will recover by ≥12 percentage points above vehicle,

BECAUSE of the following step-by-step causal chain:

1. **The TOMM20(1–33) N-terminal transmembrane anchor spontaneously inserts into the outer mitochondrial membrane (OMM) during organelle biogenesis in C2C12 myoblasts, projecting all downstream domains into the cytosol-equivalent external space without disrup

Background

Pulmonary arterial hypertension (PAH) remains one of the most lethal complications of mixed connective tissue disease (MCTD), with estimated prevalence of 10–45% depending on screening methodology. Current detection relies on echocardiographic estimation of pulmonary artery systolic pressure followed by right heart catheterization (RHC), but this approach identifies PAH only after established hemodynamic derangement, missing the critical window for early vasodilator intervention when vascular remodeling may still be partially reversible.

Angiopoietin-2 (Ang-2) is released from endothelial Weibel-Palade bodies during vascular stress and destabilizes vessel integrity by competitively antagonizing the stabilizing Tie2 receptor signal from Angiopoietin-1 (Ang-1). Elevated Ang-2/Ang-1 ratios have been reported in idiopathic PAH and systemic sclerosis-associated PAH, but longitudinal trajectory analysis in MCTD — where anti-U1 RNP-driven endothelial injury is the primary pathogenic driver — has not been systematically performed.

Hypothesis

Serial measurement of serum Ang-2/Ang-1 ratio at 3-month intervals in anti-U1 RNP-positive MCTD patients will reveal a characteristic sigmoid acceleration pattern 12–24 months before RHC-confirmed PAH (mean pulmonary artery pressure ≥20 mmHg at rest). Specifically, a sustained Ang-2/Ang-1 ratio >3.5 or a rate of change exceeding 0.4 units per quarter over two consecutive measurements will predict incident PAH with >80% sensitivity and >75% specificity, outperforming echocardiographic screening alone.

Testable Prediction

IF a structure-based small-molecule orthosteric disruptor of the DKK1 CRD2–LRP6-E3 YWTD interface — designed as a cyclic peptidomimetic of the DKK1c loop (residues 222–231), incorporating pharmacophoric mimicry of Phe205/Trp206 (hydrophobic anchor) and Leu231/Ile233/Phe234 (hydrophobic finger) with a carboxylate bioisostere engaging Asp830 — delivered via intraperitoneal injection (10–30 mg/kg, 3×/week) or localized subcutaneous depot at target tissue sites,

is administered to aged (24-month-old) C57BL/6J male and female mice with documented bone mineral density loss, impaired muscle regeneration, and elevated circulating DKK1,

THEN competitive displacement of accumulated endogenous DKK1 protein from the LRP6-E3 YWTD propeller hydrophobic patch (Phe836, Trp875, Met877, Asp830) will be observed biochemically, accompanied by: (a) ≥30% restoration of LRP6 phosphorylation at Ser1490 in bone and skeletal muscle lysates; (b) ≥25% recovery of trabecular bone volume (BV/TV by μCT) within 12 weeks; (c) improved cardiotoxin-induced tibialis anterior regeneration index; and (d) reduced serum DKK1-LRP6 co-immunoprecipitation signal — all compared to vehicle-treated aged controls,

BECAUSE:

1. DKK1 is a secreted extracellular Wnt antagonist whose plasma and tissue levels rise significantly with aging, and chronically elevated DKK1 suppresses Wnt/β-catenin signaling in bone marrow stromal cells, satellite cells, and neural progenitors, constituting a form of accumulated extracellular functional damage that passively blocks tissue repair (DKK1 elevation in aged tissues suppresses Wnt)[d

Exploring mechanisms and implications for aging biology. What evidence supports this, and how could we test it?

IF UDP-003 (Cyclarity Therapeutics; engineered hydroxypropyl-β-cyclodextrin, 7KC-selective; subcutaneous administration at the monotherapy-equivalent dose range suggested by existing pharmacokinetic data, estimated 200–400 mg/kg, 3×/week) is co-administered with lupeol (a pentacyclic triterpenoid TFEB/autophagy activator, 50 mg/kg/day oral gavage) to male and female ApoE-/- mice, aged 20 weeks with 12 weeks of established high-fat diet (HFD)-induced atherosclerosis (a post-plaque-establishment regression model),

THEN the following outcomes, measured at 8 weeks post-treatment initiation, will exceed those of UDP-003 monotherapy: (a) aortic arch 7KC content reduced by ≥50% from vehicle control (vs. ~25–35% estimated for UDP-003 monotherapy), quantified by isotope-dilution LC-MS/MS with d7-7KC internal standard; (b) plaque efferocytosis index (TUNEL+/Mac3+ co-positive ratio) improved by ≥40% relative to vehicle; (c) necrotic core fraction of en face Oil Red O plaque area reduced by ≥30%; and (d) aortic sinus CD68+ macrophage density reduced by ≥25%,

BECAUSE the following mechanistic chain operates in series:

1. Chronic 7KC accumulation within foam-cell lysosomes is the primary driver of lysosomal dysfunction in atherosclerotic plaques. Lysosomal function is markedly impaired in atherosclerosis, and restoring lysosomal competence in macrophages confers measurable anti-atherogenic effects in preclinical models (Lysosomal biogenesis induction is anti-atherogenic)[https://doi.org/10.1161/ATVBAHA]. UDP-003 monotherapy removes the lysosomal 7KC burden

Core Hypothesis

Peptides and enzymes engage in cooperative, synergistic interactions — analogous to a network of 'friendly' molecular partnerships — that collectively enhance biological efficiency and adaptability beyond what either molecule class achieves independently.

Specifically: peptides function as dynamic modulators and structural companions to enzymes, stabilizing catalytic activity, guiding substrate interactions, and orchestrating signaling cascades through cooperative binding — forming transient but functionally critical peptide-enzyme complexes.

Five Mechanistic Pillars

1. Stress-Protective Structural Stabilization — Peptides bind to enzyme surfaces under conditions of thermal, pH, or oxidative stress, acting as molecular chaperones that preserve native conformation and prevent denaturation-driven activity loss.

2. Allosteric Enhancement of Substrate Binding — Cooperative peptide binding at allosteric sites increases enzyme affinity for substrates, raising catalytic throughput (k_cat/K_M) without altering the active site directly.

3. Peptide-Mediated Enzymatic Signaling — Short signaling peptides activate or inhibit target enzymes contextually, enabling rapid, reversible regulation as an alternative to slower transcriptional control mechanisms.

IF mifepristone (10–25 mg/kg/day, oral gavage, 8 weeks) is administered to 18-month-old C57BL/6 mice of both sexes,

THEN a measurable reduction (≥30%) in senescent cell burden (p16^INK4a^, p21^CIP1^, SA-β-galactosidase) and SASP output (IL-6, IL-8/CXCL1, TNFα protein in plasma and tissue lysates) will be observed in liver, heart, and adipose tissue — quantified by RNAscope for p16/p21, ELISA for secreted SASP factors, and flow cytometry for SA-β-gal in stromal fractions —

BECAUSE the following causal chain operates specifically in aged, RAC3-depleted tissue:

1. RAC3 (Receptor-Associated Coactivator 3), a nuclear receptor coactivator that tonically suppresses early autophagy initiation and prevents p53 nuclear translocation, is progressively downregulated during aging, creating a permissive but disorganised autophagy landscape in aged cells where basal mitophagy is insufficient to clear dysfunctional mitochondria (RAC3 inhibits early autophagy and is downregulated in aging)[https://doi.org/10.1038/cddis.2015.218].

2. Mifepristone, as a potent glucocorticoid receptor (GR) and progesterone receptor (PR) antagonist, competes with coactivators including RAC3 at the receptor interface, thereby disrupting the residual RAC3-GR complex that in aged cells partially restrains autophagy flux. By blocking GR-coactivator assembly, mifepristone disinhibits the ULK1/Beclin-1 autophagy initiation complex [SPECULATIVE — direct RAC3-GR-mifepristone biochemistry not yet demonstrated; inferred from RAC3's role as a steroid receptor coactivator and mifepristone's known coactivator-di

This hypothesis explores endogenous retroviruses as aging clocks. What does the evidence suggest, and how might we test it?

Background: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) share overlapping clinical features, yet their synovial biology diverges at the molecular level. Cell-free DNA (cfDNA) fragmentomics—analyzing fragment length distributions, end-motif sequences, and nucleosome positioning patterns—has transformed liquid biopsy in oncology but remains unexplored in inflammatory arthritis.

Hypothesis: cfDNA extracted from synovial fluid of PsA patients exhibits a distinct fragmentomic signature characterized by (1) enrichment of short fragments (<150 bp) reflecting neutrophil extracellular trap (NET)-derived DNA, (2) specific 4-mer end-motif frequencies correlating with DNAL1/DNASE1L3 activity ratios, and (3) nucleosome footprints at IL-17A/IL-17F and IL-23R promoter regions that distinguish PsA from RA with >85% AUROC. Furthermore, baseline fragmentomic entropy—quantified as Shannon entropy across the fragment length distribution—predicts clinical response to IL-17 inhibitors (secukinumab/ixekizumab) at week 8, with low-entropy profiles (dominated by NET-derived short fragments) indicating active neutrophilic inflammation amenable to IL-17 blockade.

Testable predictions: (1) In a prospective cohort of 120 patients (60 PsA, 60 RA), synovial fluid cfDNA fragmentomic classifiers achieve AUROC >0.85 for differential diagnosis. (2) Baseline Shannon entropy of the fragment length distribution correlates inversely with ACR20 response at week 8 in PsA patients initiating IL-17 inhibitors (Spearman ρ < −0.45, p < 0.01). (3) Nucleosome occupancy at the IL-17A promoter in

IF intra-articular co-administration of hydroxychloroquine (HCQ, 50 μg) combined with low-dose ouabain (a cardiac glycoside Na⁺/K⁺-ATPase inhibitor, estimated 5–15 μg based on in vitro selectivity windows) is delivered biweekly for 8 weeks into the knee joints of 24-month-old male C57BL/6J mice,

THEN selective elimination of ≥40% of p16^INK4a-positive senescent chondrocytes will be achieved — quantified by immunohistochemistry across ≥6 cartilage sections per animal counting ≥200 chondrocytes per section — accompanied by improved modified Mankin scores and rotarod performance, and without a >20% increase in cleaved caspase-3 immunopositivity in non-senescent chondrocytes,

BECAUSE the following causal chain links the intervention to the outcome:

1. Aged articular chondrocytes that have entered replicative or stress-induced senescence accumulate a hypertrophic lysosomal compartment, driving markedly elevated SA-β-gal activity and progressive deposition of lipofuscin and oxidized protein aggregates that cannot be cleared by normal autophagy; this creates a state of chronic lysosomal stress in which the cell's entire proteostatic survival depends on sustained, high-throughput autophagic flux — a state termed "lysosomal addiction" (p16^INK4a as a robust biomarker of this molecular aging state in mouse and human cartilage)[https://doi.org/10.1111/acel.12771].

2. Senescent cells in this high-lysosomal-burden state upregulate basal autophagy flux as a compensatory survival mechanism; this elevated flux paradoxically sensitizes them to agents that interrupt autophagy, because bl